SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation E484K


Basic Characteristics of Mutations
Mutation Site E484K
Mutation Site Sentence Lineage P.1 acquired 17 mutations; including a trio in the spike protein (K417T; E484K; and N501Y) associated with increased binding to the human ACE2 (angiotensin-converting enzyme 2) receptor.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype P.1
Viral Reference -
Functional Impact and Mechanisms
Disease COVID-19    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location Brazil
Literature Information
PMID 33853970
Title Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Author Faria NR,Mellan TA,Whittaker C,Claro IM,Candido DDS,Mishra S,Crispim MAE,Sales FCS,Hawryluk I,McCrone JT,Hulswit RJG,Franco LAM,Ramundo MS,de Jesus JG,Andrade PS,Coletti TM,Ferreira GM,Silva CAM,Manuli ER,Pereira RHM,Peixoto PS,Kraemer MUG,Gaburo N Jr,Camilo CDC,Hoeltgebaum H,Souza WM,Rocha EC,de Souza LM,de Pinho MC,Araujo LJT,Malta FSV,de Lima AB,Silva JDP,Zauli DAG,Ferreira ACS,Schnekenberg RP,Laydon DJ,Walker PGT,Schluter HM,Dos Santos ALP,Vidal MS,Del Caro VS,Filho RMF,Dos Santos HM,Aguiar RS,Proenca-Modena JL,Nelson B,Hay JA,Monod M,Miscouridou X,Coupland H,Sonabend R,Vollmer M,Gandy A,Prete CA Jr,Nascimento VH,Suchard MA,Bowden TA,Pond SLK,Wu CH,Ratmann O,Ferguson NM,Dye C,Loman NJ,Lemey P,Rambaut A,Fraiji NA,Carvalho MDPSS,Pybus OG,Flaxman S,Bhatt S,Sabino EC
Journal Science (New York, N.Y.)
Journal Info 2021 May 21;372(6544):815-821
Abstract Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Manaus, Brazil, resurged in late 2020 despite previously high levels of infection. Genome sequencing of viruses sampled in Manaus between November 2020 and January 2021 revealed the emergence and circulation of a novel SARS-CoV-2 variant of concern. Lineage P.1 acquired 17 mutations, including a trio in the spike protein (K417T, E484K, and N501Y) associated with increased binding to the human ACE2 (angiotensin-converting enzyme 2) receptor. Molecular clock analysis shows that P.1 emergence occurred around mid-November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.7- to 2.4-fold more transmissible and that previous (non-P.1) infection provides 54 to 79% of the protection against infection with P.1 that it provides against non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.